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This study assessed the pharmacokinetics and dosing adequacy of piperacillin in febrile neutropenic patients after the first dose.
Pharmacokinetic analysis was performed using noncompartmental methods. We observed an elevated volume of distribution
(29.7 8.0 liters [mean standard deviation]) and clearance (20.2 7.5 liters/h) compared to data from other patient popula-
tions. Antibiotic exposure did not consistently result in therapeutic targets. We conclude that alternative dosing strategies
guided by therapeutic drug monitoring may be required to optimize exposure.
Febrile neutropenia is amedical emergency associatedwith highmortality (1). The immediate administration of broad-spec-
trum antibiotics is crucial for reducing the risk of mortality (2).
-lactam antibiotics active against Pseudomonas aeruginosa, such
as piperacillin-tazobactam, are common first-line empirical
agents used to treat this condition. Emerging data suggest that the
standard dosing regimens for these antibiotics may not provide
adequate exposure due to pharmacokinetic (PK) alterations em-
anating from pathophysiological processes associated with neu-
tropenia (3, 4). More specifically, the proportion of the dosing
interval in which the free-drug concentration remains above the
MIC (fTMIC) may be diminished. For -lactams, fTMIC is the
pharmacokinetic-pharmacodynamic (PK-PD) index that best
correlates with clinical outcome (5).
Most of the evidence for the altered -lactam PK and asso-
ciated poor PK-PD target attainment in febrile neutropenic
patients is available for other antibiotics, such as ceftazidime
(6) and meropenem (7). The data are meager for piperacillin in
this regard, even though it is commonly considered the pre-
ferred -lactam for febrile neutropenia. To our knowledge,
there is no well-described recent study except the works of
Drusano et al. (8, 9), which reported no PK alterations in fe-
brile neutropenic patients, a finding which is contrary to the
recent reports of PK alterations and variability across many
antibiotic classes (3, 4). Therefore, the aims of this study were
to describe the PK of piperacillin in patients with febrile neu-
tropenia following chemotherapy for hematological malig-
nancy and to assess the adequacy of the standard initial dosing
to attain the recommended pharmacodynamic (PD) target
against all possible organisms during the first dosing interval.
Twelvepatients18yearsof agewithhematologicalmalignancies
were enrolled when prescribed piperacillin-tazobactam after devel-
oping febrile neutropenia. Febrile neutropenia was defined as the
presence of a single oral temperature of38.3°C (101°F) or a tem-
perature of 38.0°C (100.4°F) for 1 h, with either a neutrophil
count of 500 cells/mm3 or a count of 1,000 cells/mm3 with a
predicted decrease to500 cells/mm3 (2). Patients were excluded if
they had a known/suspected allergy to -lactams, marked renal fail-
ure (defined as a glomerular filtration rate [GFR] of20ml/min) or
hepatic impairment (transaminases 500U/liter) orwere pregnant.
Ethics approval for the study was granted by the human research
ethics committees of The Queen Elizabeth Hospital (HREC/12/
TQEHLMH/157) and the University of South Australia (application
no. 0000031077). All patients received 4.5 g piperacillin-tazobactam
every 8 h via intravenous bolus infusion over 30min, followed by 15
to 20 min of line flushing. In addition, all patients received a single
7-mg/kg of body weight dose of gentamicin.
Serial blood samples were collected just prior to the first
dose, at the end of line flushing, and at 1 h, 2 h, 3 h, 4 h, 5 h, 6
h, and 7 h after the start of infusion, and then a final sample was
collected just before the second dose. The total plasma concen-
trations of piperacillin were quantified using a validated liquid
chromatography tandem mass spectrometry method. Non-
compartmental pharmacokinetic analysis was performed using
PKSolver (10). The fTMIC was estimated after the first dose
from the log-linear elimination phase. First, the terminal elim-
ination constant (kel) was estimated with the PKSolver software
(10). Next, considering 30% protein binding for piperacillin
(11), the fTMIC was calculated for P. aeruginosa and Enterobac-
teriaceae based on the breakpoints of the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) (12) and the
Clinical and Laboratory Standards Institute (CLSI) (13). As this
study aims to assess the adequacy of the initial dosing against all
possible organisms, we selected P. aeruginosa and Enterobacteria-
ceae, which have the highest MIC breakpoints according to inter-
pretive criteria of the EUCAST and CLSI.
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The demographic characteristics of the study participants
are given in Table 1. All patients were febrile and neutropenic,
with cell counts too low to perform differential counts. Blood
cultures were positive for infection in four patients (patients 1,
3, 9, and 10), and the organisms isolated were organisms re-
sembling staphylococci, Enterobacter aerogenes, P. aeruginosa,
and Escherichia coli, respectively. The plasma concentration-time
profile for total piperacillin concentration after a single dose of 4.5
g piperacillin-tazobactam is depicted in Fig. 1. Pharmacokinetic
parameter estimates of the individual study participants are given
in Table 2.
We observed an elevated volume of distribution (V) (29.7 
8.0 liters [mean standard deviation]) and clearance (CL) (20.2
 7.5 liters/h) for the cohort in this study. Different factors may
contribute to the expansion of the V. One important factor is the
alteration of capillary permeability and subsequent extravasation
of vascular fluid during infection, which is mediated by various
factors (14). The increase might also occur due to hypoalbumin-
emia, which is common in hematological malignancies and was
observed for all participants in this study (Table 1). Low albumin
concentrations reduce plasma oncotic pressure, subsequently
leading to enhanced fluid extravasation. However, the effect of
hypoalbuminemia is most prominent for highly protein-bound
antibiotics and therefore might have limited contribution toward
the increased piperacillin V observed in this study (30% protein
binding) (4, 15). Changes in the glomerular filtration rate (GFR)
have been implicated in the variability of antibiotic CL in febrile
patients with hematological malignancies (6). A very high GFR
value is common in patients undergoing chemotherapy (16) and
may contribute to elevated CL. Serum creatinine clearance (deter-
mined using the Cockcroft-Gault formula) was also distinctively
high for some participants (Table 1, patients 8 to 12), indicating
the presence of augmented renal clearance contributing to the
significant increase in individual piperacillin clearances (Table 2).















1 Acute myeloid leukemia M 61 82 172 88 65.3 27 50 23
2 Acute myeloid leukemia M 74 100 175 61 73.7 25 13 7
3 Acute myeloid leukemia F 70 64 164 57 72.6 29 37 23
4 Multiple myeloma F 64 53 153 67 62.8 28 16 24
5 Lymphoma F 74 54 155 78 55.4 26 27 19
6 Acute myeloid leukemia M 79 69 173 95 51.4 33 21 48
7 Acute lymphoblastic
leukemia
M 68 63 175 70 78.6 23 25 15
8 Acute lymphoblastic
leukemia
F 54 71 171 44 119.6 27 14 10
9 Acute myeloid leukemia M 63 79 184 66 96.9 26 142 102
10 Multiple myeloma M 65 100 174 46 109.7 31 12 14
11 Multiple myeloma M 53 91 184 61 110.4 30 37 19




















a M, male; F, female.
b Using the Cockcroft-Gault formula.
c ALT, alanine aminotransferase; AST, aspartate transaminase.
FIG1 Plasma concentration-time profile for total piperacillin concentration after a single dose of 4.5 g piperacillin-tazobactam in 12 febrile neutropenic patients
with hematological malignancies.
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In fact, drug exposure was moderately correlated with creatinine
clearance (r0.663, P 0.05). Augmented renal clearance in
febrile patients might occur in a way similar to that in critically ill
septic patients due to increased renal blood flow secondary to a
hyperdynamic cardiovascular state (17). However, in hyperdy-
namic patients in whom there is no stable creatinine concentra-
tion, predictive equations of creatinine clearance and GFR are
likely to be incorrect in assessing the rapidly changing renal func-
tion and, hence, antibiotic CL (18, 19).
The elevated CL and significant expansion of the V in our
patients explain the very low observed trough concentrations
(median, 0.5 mg/liter). This is far below the clinical suscepti-
bility breakpoint of expected pathogens, such as Enterobacteri-
aceae (8 mg/liter for EUCAST and 16 mg/liter for CLSI) and P.
aeruginosa (16 mg/liter for CLSI and EUCAST) (12, 13). The
fTMIC achieved for P. aeruginosa after the first dose (Fig. 2) was
suboptimal compared to the conventionally recommended PD
targets of about 50% to 60% fTMIC (20). Similarly, for Entero-
bacteriaceae, the fTMIC was suboptimal for the majority of par-
ticipants when conventional PD targets were considered and in all
patients when 100% fTMICwas considered as a target. There is an
emerging understanding that neutropenic patients may require a
higher PK-PD index for a successful outcome due to their com-
promised immune response. Ariano et al. (21), for instance,
showed that for meropenem, an 80% clinical response is observed
when the fTMIC is75%, a value much higher than the conven-
tional 40% fTMIC. Similarly, for penicillins and cephalosporins,
which lack postantibiotic effect against Gram-negative organisms,
previous data from some animal studies have indicated that in the
settings of profound neutropenia, free concentrations should be
greater than the MIC for 90% to 100% of the dosing interval to
ensure efficacy (22). This is well supported by studies that dem-
onstrate the profound effect of host immunity on PD parameters
(23–25). In immunocompromised hosts, a more aggressive anti-
biotic action through increased antibiotic exposure time may be
required to achieve the same response as in immunocompetent
hosts.
Considering 100% fTMIC, our results indicate that the stan-
dard bolus dose of 4.5 g piperacillin-tazobactam every 8 h is un-
likely to provide optimal exposure against P. aeruginosa and En-
terobacteriaceae (Fig. 2). Optimal exposure should be achieved as
early as possible to reduce the risk ofmortality (26). In the current
study, concentrations remained below the MIC of P. aeruginosa
for about 5 to 6 h of the first dose interval. Such extended subin-
hibitory exposure should be avoided to reduce the risk of selecting
resistant organisms (27).
We believe that the present intermittent dosing regimen
should be reviewed and replaced with new dosing strategies
that ensure adequate antibiotic exposure and reduce the risk of
the emergence of antibiotic resistance. Better exposure can be
achieved with more frequent administration of the dose (e.g.,
4.5 g every 6 h), which in effect increases the total daily dose.
TABLE 2 Pharmacokinetic parameter estimates of piperacillin after a single dose of 4.5 g piperacillin-tazobactam in 12 febrile neutropenic patients
with hematological malignancies
Patient no. or









(mg/liter · h2)e MRT (h)f Vz (liters)
g Vss (liters)
h CL (liters/h) t1/2 (h)
i
1 125.7 0.5 174.6 175.5 285.3 1.4 38.3 31.4 22.8 1.2
2 119.5 1.1 196.4 198.1 343.9 1.5 31.6 30.0 20.2 1.1
3 144 0.5 239.0 239.7 409.8 1.5 23.8 24.4 16.7 1.0
4 228 6.1 419.4 433.1 1,026.4 2.1 20.7 19.6 9.2 1.6
5 148.5 2.5 292.6 297.2 618.9 1.8 25.0 24.7 13.5 1.3
6 129.5 5.2 283.8 298.1 772.9 2.3 36.6 31.4 13.4 1.9
7 180.5 0.9 288.9 290.2 493.1 1.4 19.8 20.0 13.8 1.0
8 161.5 0.2 238.6 238.8 346.3 1.2 17.9 20.1 16.7 0.7
9 97.5 0.2 150.1 150.4 234.5 1.3 40.7 34.8 26.6 1.1
10 92.65 0.4 143.2 143.8 247.7 1.5 48.6 41.0 27.8 1.2
11 86.6 0.2 124.0 124.3 180.0 1.2 37.9 38.6 32.2 0.8
12 89.8 130.1 133.4 215.5 1.4 38.1 41.0 30.0 0.9




127.6 (96.3–151.8) 0.5 (0.3–1.8) 217.5 (148.4–285.1) 218.4 (148.8–291.9) 345.1 (244.4–524.6) 1.5 (1.4–1.6) 34.1 (23–38.2) 30.7 (23.3–35.7) 18.5 (13.7–26.9) 1.1 (1.0–1.2)
a Cmax, maximum concentration of drug in serum.
b Cmin, minimum concentration of drug in serum.
c AUC0-t, area under the concentration-time curve from 0 h to a given time.
d AUC0-inf, area under the concentration-time curve from 0 h to infinity.
e AUMC0-inf, area under the moment curve from 0 h to infinity.
f MRT, mean residence time.
g Vz, apparent volume of distribution during terminal phase.
h Vss, volume of distribution at steady state.
i t1/2, half-life.
FIG 2 Pharmacodynamic target attainment after a single dose of 4.5 g pipera-
cillin-tazobactam in 12 febrile neutropenic patients with hematological malig-
nancies (considering EUCASTMIC breakpoints for Enterobacteriaceae and P.
aeruginosa).
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The mode of administration used (i.e., 30-min bolus infusion)
could also be optimized. The use of extended infusion (EI) or
continuous infusion (CI) is an attractive approach to maximize
the fTMIC without increasing the total daily dose (28). In com-
bination with a loading dose, EI or CI can be used to avoid the
initial suboptimal exposure observed with the intermittent
schedule in this study. CI may be practically challenging, as it
requires a dedicated intravenous (i.v.) line, which may not be
available given that patients often receive a number of other
drugs and perhaps nutritional support. EI is more practical in
this regard, allowing sufficient line access for other purposes.
Another challenge is that a fixed EI or CI regimen may not
reach the PD target consistently in all patients due to the vari-
ability in CL and V. Dose individualization through therapeu-
tic-drug monitoring (TDM) may be useful to ensure optimal
exposure in every patient.
Often, culture results are not available initially for use in
TDM. We therefore suggest initial dosing aimed at organisms
with high MICs, such as P. aeruginosa, and then dosing can be
readjusted based on the specific organismMIC. Local institutional
antibiograms should be utilized whenever available, as there is
geographical and institution-to-institution variability in suscepti-
bility.However, in the absence of such data, EUCAST/CLSI break-
points provide reasonable references for use in TDM. This has
been well demonstrated for piperacillin (and other -lactam an-
tibiotics) in critically ill patients who exhibit PK alterations similar
to those observed in this study (29). However, it has not yet been
described in febrile neutropenic patients. Further clinical studies
are required to assess the utility of TDM of piperacillin in febrile
neutropenic patients.
In conclusion, the observed high V and CL suggest altered PK
of piperacillin in febrile neutropenic patients. Standard intermit-
tent dosing of 4.5 g piperacillin-tazobactam (i.v. bolus, every 8 h)
resulted in suboptimal antibiotic exposure and therefore was not
sufficient. We recommend TDM-guided optimization with EI or
adjusted dosing frequency to ensure exposure to inhibitory con-
centrations for the entire dosing interval.
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